Table 5.
N-glycan abundancies for the 4 analysed mAbs obtained through peptide mapping analysis via LC-MS/MS. Abundancies are expressed as % respect to the total abundance of the peptide EEQYNSTYR and/or TKPREEQYNSTYR containing 1 miscleavage and were calculated on triplicate independent sample preparations.
| Glycoform | % Relative abundance (n = 3) |
|||
|---|---|---|---|---|
| Bevacizumab | Trastuzumab | Infliximab | Rituximab | |
| A1G0 | 0.84 | 2.30 | 2.47 | 0.34 |
| A1G0F | 6.61 | 6.98 | 8.78 | 5.06 |
| A1G0M4 | – | – | 1.70 | – |
| A1G0M5 | – | – | 3.87 | – |
| A1G0M5F | – | – | 1.83 | – |
| A1G1 | – | 0.59 | – | – |
| A1G1F | 0.76 | 2.18 | 3.91 | 1.80 |
| A1G1M5 | – | – | 1.36 | – |
| A1G1M5F | – | – | 0.52 | – |
| A1S1 | – | 0.09 | – | – |
| A1S1F | – | 0.40 | – | 0.21 |
| A1S1M5 (A1Sg1M4F) | – | – | 0.51 | – |
| A1Sg1 | – | – | 0.32 | – |
| A1Sg1F | – | – | 2.10 | – |
| A2G0 | 2.33 | 5.38 | 1.66 | 1.61 |
| A2G0F | 74.86 | 39.88 | 44.86 | 40.77 |
| A2G1 | – | 1.94 | 0.37 | 0.63 |
| A2G1F | 10.77 | 32.28 | 18.60 | 39.80 |
| A2G2 | – | 0.16 | – | – |
| A2G2F | 0.73 | 5.19 | 2.40 | 7.51 |
| A2S1G0F | – | 0.44 | – | 0.48 |
| A2S1G1F | – | 0.65 | – | 1.00 |
| A2S2F | – | 0.23 | – | 0.48 |
| A3G1F | – | 0.16 | – | 0.16 |
| A2Sg1G0F | – | – | 0.76 | – |
| M3 | – | 0.16 | – | – |
| M4 | – | 0.15 | 0.09 | – |
| M5 | 0.87 | 2.87 | 7.33 | 1.45 |
| M6 | – | 0.20 | 0.12 | 0.29 |
| Unglycosylated | 5.35 | 1.44 | 0.39 | 1.34 |